Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk
Acta Pharmaceutica · 01.06.2022 · 72 (2) · 303-315
DOI: 10.2478/acph-2022-0018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica, online erschienen am 30.12.2021. Verfasst von Ana Vavlukis und 6 weiteren Autor:innen. Beteiligte Einrichtung: 1University Ss Cyril and Methodius Faculty of Pharmacy 1000 Skopje, RN Macedonia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Rosuvastatin Calcium. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular risk. Data was collected from patients’ records, physical examination and blood sampling. Subjects were assigned to rosuvastatin 20 mg per day. Rosuvastatin significantly decreased C-reactive protein ( p = 0.045), and increased vascular endothelial growth factor ( p = 0.004) and epidermal growth factor ( p = 0.009). A multivariate analysis identified total cholesterol ( p = 0.027) and vascular endothelial growth factor ( p = 0.011) to be independently associated with rosuvastatin treatment. Given beneficial/harmful role of growth factors, vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), in cardiovascular disease, one would suggest the need for routine monitoring of growth factor levels, especially in patients on long-term statin therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1University Ss Cyril and Methodius Faculty of Pharmacy 1000 Skopje, RN Macedonia.
- 2University Ss Cyril and Methodius Faculty of Medicine 1000 Skopje, RN Macedonia.
Zitieren
APA
Vavlukis, A., Vavlukis, M., Dimovski, A., Petrushevska, G., Eftimov, A., Domazetovska, S., & Mladenovska, K. (2022). Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica, 72(2), 303-315. https://doi.org/10.2478/acph-2022-0018
Vancouver
Vavlukis A, Vavlukis M, Dimovski A, Petrushevska G, Eftimov A, Domazetovska S, et al. Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk. Acta Pharmaceutica. 2022;72(2):303-315. doi:10.2478/acph-2022-0018
BibTeX
@article{Vavlukis2022,
author = {Vavlukis, Ana and Vavlukis, Marija and Dimovski, Aleksandar and Petrushevska, Gordana and Eftimov, Aleksandar and Domazetovska, Sashka and Mladenovska, Kristina},
title = {Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk},
journal = {Acta Pharmaceutica},
year = {2022},
volume = {72},
number = {2},
pages = {303--315},
doi = {10.2478/acph-2022-0018}
}
EUVIMED